28 Oct 2014 06:18
Panmure Gordon chose to reiterate its 'buy' recommendation on Shire even though the $54bn pursuit by Abbvie is now officially over, highlighting an "opportunity" for investors to pick up shares after recent falls. Analyst Savvas Neophytou said that the company's rare diseases business still remains
Read moreBroker Shore Capital welcomed transport group Go-Ahead's latest update but said it was keener on rival Stagecoach. Go-Ahead said in a first-quarter trading update on Tuesday that commercial and concessionary passenger numbers on its regional buses were broadly flat year-on-year, with weakness in the
Read more